Testosterone News and Research

Latest Testosterone News and Research

BioSante receives two new US patents covering 2A/Furin technology for expressing proteins

BioSante Pharmaceuticals, Inc. today announced the receipt of two US new patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,709,224, covers methods for manufacturing recombinant antibodies. By incorporating our 2A/Furin technology into antibody-expression in viral vectors it is possible to rapidly generate stable, high producing antibody cell lines.

18 May 2010

Low testosterone levels can impact sleep quality

At 30 years old, male testosterone levels drop by one to two percent annually. By age 40, men's quality of sleep begins to diminish. Could there be a link between decreased testosterone and reduced sleep?

15 May 2010

BioSante Pharmaceuticals first-quarter net loss increases to $10.5 million

BioSante Pharmaceuticals, Inc. today reported on its recent developments and financial results for the first quarter, and its cash balance as of March 31, 2010.

14 May 2010

RMEI, PIM sponsor continuing education series on castration-resistant prostate cancer

Castration-resistant prostate cancer (CRPC), defined as tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Current treatment regimens are complicated by toxicities and a low rate of relapse-free survival. Many novel therapies in clinical trials offer hope for patients with this challenging diagnosis. Healthcare professionals who are treating CRPC must stay abreast of these emerging therapies to ensure optimal care for these patients.

14 May 2010

Columbia Laboratories reports 34% increase in net revenues from U.S. sales of progesterone products

Columbia Laboratories, Inc. today announced financial results for the three-month period ended March 31, 2010.

6 May 2010

CPEX Pharmaceuticals reports record quarterly royalty revenues from Testim sales

CPEX Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010. For the quarter CPEX reported revenues of $5.3 million and a net loss of $940,000.

5 May 2010

Australian researchers show positive effect of growth hormone on athletic performance

Australian researchers have published the results of a study, for the first time showing a positive effect of growth hormone on athletic performance.

5 May 2010

HGH improves athletic performance: Study

A study released today in Annals of Internal Medicine, the flagship journal of the American College of Physicians, finds that human growth hormone improves sprint capacity in healthy recreational athletes. This is the first trial to demonstrate that HGH improves athletic performance.

4 May 2010

LA BioMed receives $1.5M in grant to study contraceptive for men

As the birth control pill marks its 50th birthday this month, Los Angeles Biomedical Research Institute announced today that it has received $1.5 million in grant funding to study a contraceptive for men that uses a combination of two hormonal gels applied to the skin of the arm and abdomen.

4 May 2010

Early or delayed puberty can trigger antisocial behavior in adolescent boys

Puberty that arrives earlier or later in adolescent boys relative to their peers can trigger chemicals that are related to antisocial behavior, according to researchers, whose findings have key implications for parents with aggressive boys.

4 May 2010

Obese men more likely to have low testosterone than non-obese men: HIM study

Obesity, a condition linked to heart disease and diabetes, now appears to be associated with another health problem, but one that affects men only -- low testosterone levels.

4 May 2010

Growth hormone boosts sprinting capacity in athletes but may have serious side effects

Human Growth Hormone (hGH) has long been used among athletes and body builders for stronger and a more muscular bodies over the past four decades. However it is only now that Sydney-based researchers have published a study that shows that hGH offers no such benefits.

3 May 2010

FDA issues advisory on prostate cancer drugs

Gonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several studies by the U.S. Food and Drug Administration.

3 May 2010

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

3 May 2010

Update on BioSante cancer vaccine portfolio to be presented at BIO International Convention

BioSante Pharmaceuticals, Inc. will present a BioSante cancer vaccine portfolio update at the BIO International Convention, which will take place May 3-6 in Chicago, Illinois.

30 Apr 2010

Antares Pharma, Uman Pharma announce strategic alliance for VIBEX MTX

Antares Pharma, Inc., a leader in self-injection drug delivery technology and Uman Pharma, a manufacturer of top-quality injectable pharmaceutical products based in Quebec, Canada, today announced the formation of a strategic alliance covering Antares' VIBEX™ MTX.

27 Apr 2010

Men with erectile dysfunction, low testosterone at higher risk of death from cardiovascular disease

Research presented at the European Congress of Endocrinology shows for the first time that men with erectile dysfunction and low testosterone have a higher than normal risk of dying from cardiovascular disease. Further work from the same research group shows that obesity is also associated with an impairment of blood flow to the penis, which in turn is also associated with cardiovascular disease in men with erectile dysfunction.

27 Apr 2010

BioSante signs Option Agreement to obtain non-exclusive worldwide license for 2A/Furin technology

BioSante Pharmaceuticals, Inc. today announced that it has entered into an Option Agreement with an undisclosed large multi-national pharmaceutical company to obtain a non-exclusive worldwide license for the use of BioSante's 2A/Furin technology in the expression of antibodies.

26 Apr 2010

CPEX recommends shareholders to take no action on Arcadia's unsolicited tender offer

The Board of Directors of CPEX Pharmaceuticals Inc., today recommended that its shareholders take no action at this time in response to the announcement by Arcadia Capital Advisors, LLC through RSR Acquisition Co. and its principal Richard Rofé that it has made an unsolicited conditional tender offer to acquire all of the outstanding shares of CPEX for $16.00 per share in cash.

24 Apr 2010

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on CRPC

Castrate-refractory prostate cancer, which is characterized by tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Standardized guidelines for the treatment of CRPC are lacking, and a number of factors must be considered when deciding between second-line hormonal therapy and chemotherapy.

23 Apr 2010

Testosterone News and Research

Latest Testosterone News and Research

BioSante receives two new US patents covering 2A/Furin technology for expressing proteins

Low testosterone levels can impact sleep quality

BioSante Pharmaceuticals first-quarter net loss increases to $10.5 million

RMEI, PIM sponsor continuing education series on castration-resistant prostate cancer

Columbia Laboratories reports 34% increase in net revenues from U.S. sales of progesterone products

CPEX Pharmaceuticals reports record quarterly royalty revenues from Testim sales

Australian researchers show positive effect of growth hormone on athletic performance

HGH improves athletic performance: Study

LA BioMed receives $1.5M in grant to study contraceptive for men

Early or delayed puberty can trigger antisocial behavior in adolescent boys

Obese men more likely to have low testosterone than non-obese men: HIM study

Growth hormone boosts sprinting capacity in athletes but may have serious side effects

FDA issues advisory on prostate cancer drugs

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

Update on BioSante cancer vaccine portfolio to be presented at BIO International Convention

Antares Pharma, Uman Pharma announce strategic alliance for VIBEX MTX

Men with erectile dysfunction, low testosterone at higher risk of death from cardiovascular disease

BioSante signs Option Agreement to obtain non-exclusive worldwide license for 2A/Furin technology

CPEX recommends shareholders to take no action on Arcadia's unsolicited tender offer

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on CRPC

Viva Saliva Book: The ultimate guide to saliva Book preview Download eBook

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

The evolution of OCT for retinal imaging and disease intervention

Testosterone News and Research

Latest Testosterone News and Research

Viva Saliva Book: The ultimate guide to saliva Book preview Download eBook

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

The evolution of OCT for retinal imaging and disease intervention

Newsletters you may be interested in